Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a clinical study titled A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype. The study aims to assess the safety and tolerability of LY3849891 in individuals with MASLD, focusing on those with a specific genetic marker. This research holds significance as it explores potential treatments for liver diseases linked to metabolic dysfunction.
The intervention being tested is LY3849891, a drug administered subcutaneously. It is designed to evaluate its effects on liver disease by measuring safety, tolerability, and how the body processes the drug.
The study employs a randomized, parallel assignment model with double masking, meaning both participants and investigators are unaware of who receives the drug or placebo. The primary purpose is basic science, aiming to gather foundational data on the drug’s effects.
The study began on June 8, 2022, and is currently recruiting participants. The last update was submitted on July 22, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This study update could influence Eli Lilly’s stock performance by showcasing their commitment to innovative treatments for liver diseases. Positive results might boost investor confidence, although competition in the pharmaceutical industry remains a factor.
The study is ongoing, with further details available on the ClinicalTrials portal.